Abstract
Brain imaging of cerebral blood flow and glucose metabolism has been playing key roles in describing pathophysiology of Parkinson’s disease (PD) and Huntington’s disease (HD), respectively. Many biomarkers have been developed in recent years to investigate the abnormality in molecular substrate, track the time course of disease progression, and evaluate the efficacy of novel experimental therapeutics. A growing body of literature has emerged on neurobiology of these two movement disorders in resting states and in response to brain activation tasks. In this paper, we review the latest applications of these approaches in patients and normal volunteers at rest conditions. The discussions focus on brain mapping studies with univariate and multivariate statistical analyses on a voxel basis. In particular, we present data to validate the reproducibility and reliability of unique spatial covariance patterns related with PD and HD.
Similar content being viewed by others
Reference
Worsley KJ, Poline JB, Friston KJ, Evans AC (1997) Characterizing the response of PET and fMRI data using multivariate linear models. NeuroImage 6:305–319
Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD (1996) Detecting activations in PET and fMRI: levels of inference and power. NeuroImage 4:223–235
Lin FH, McIntosh AR, Agnew JA, Eden GF, Zeffiro TA, Belliveau JW (2003) Multivariate analysis of neuronal interactions in the generalized partial least squares framework: simulations and empirical studies. NeuroImage 20:625–642
Alexander G, Moeller J (1994) Application of the scaled subprofile model to functional imaging in neuropsychiatric disorders: a principal component approach to modeling brain function in disease. Hum Brain Mapp 2:1–16
Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. (1994) The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14:783–801
Zuendorf G, Kerrouche N, Herholz K, Baron JC (2003) Efficient principal component analysis for multivariate 3D voxel-based mapping of brain functional imaging data sets as applied to FDG-PET and normal aging. Hum Brain Mapp 18:13–21
Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D (2006) Abnormal metabolic network activity in Parkinson’s disease: test–retest reproducibility. J Cereb Blood Flow Metab (in press). DOI 10.1038/sj.jcbfm.9600358
Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Mentis MJ, et al. (2001) Metabolic correlates of levodopa response in Parkinson’s disease. Neurology 57:2083–2088
Trost M, Carbon M, Edwards C, Ma Y, Raymond D, Mentis MJ, et al. (2002) Primary dystonia: is abnormal functional brain architecture linked to genotype? Ann Neurol 52:853–856
Scarmeas N, Habeck CG, Zarahn E, Anderson KE, Park A, Hilton J, et al. (2004) Covariance PET patterns in early Alzheimer’s disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance. NeuroImage 23:35–45
Eckert T, Eidelberg D (2005) Neuroimaging and therapeutics in movement disorders. NeuroRx 2:361–371
Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. (2004) MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63:2332–2340
Huang C, Eidelberg D, Habeck C, Moeller J, Svensson L, Tarabula T, et al. (2006) Imaging markers of mild cognitive impairment: multivariate analysis of CBF SPECT. Neurobiol Aging (in press). DOI 10.1016/j.neurobiolaging.2006.05.017
Salmon E, Kerrouche N, Herholz K, Perani D, Holthoff V, Beuthien-Baumann B, et al. (2006) Decomposition of metabolic brain clusters in the frontal variant of frontotemporal dementia. NeuroImage 30:871–878
Kerrouche N, Herholz K, Mielke R, Holthoff V, Baron JC (2006) 18FDG-PET in vascular dementia: differentiation from Alzheimer’s disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab 26:1213–1221
Eustache F, Piolino P, Giffard B, Viader F, De La Sayette V, Baron JC, et al. (2004) ‘In the course of time’: a PET study of the cerebral substrates of autobiographical amnesia in Alzheimer’s disease. Brain 127:1549–1560
Carbon M, Su S, Dhawan V, Raymond D, Bressman S, Eidelberg D (2004) Regional metabolism in primary torsion dystonia: effects of penetrance and genotype. Neurology 62:1384–1390
Asanuma K, Ma Y, Huang C, Carbon M, Edwards C, Raymond D, et al. (2005) The metabolic pathology of dopa-responsive dystonia. Ann Neurol 57:596–600
Ghilardi MF, Carbon M, Silvestri G, Dhawan V, Tagliati M, Bressman S, et al. (2003) Impaired sequence learning in carriers of the DYT1 dystonia mutation. Ann Neurol 54:102–109
Detante O, Vercueil L, Thobois S, Broussolle E, Costes N, Lavenne F, et al. (2004) Globus pallidus internus stimulation in primary generalized dystonia: a H215O PET study. Brain 127:1899–1908
Yianni J, Bradley K, Soper N, O’Sullivan V, Nandi D, Gregory R, et al. (2005) Effect of GPi DBS on functional imaging of the brain in dystonia. J Clin Neurosci 12:137–141
Ma Y, Dhawan V, Freed C, Fahn S, Eidelberg D (2005) PET and embryonic dopamine cell transplantation in Parkinson’s disease. In: Broderick PA, Rabni DN, Kolodny EH (eds) Bioimaging in neurodegeneration. New Jersey: Humana Press, pp 45–58
Brownell AL, Canales K, Chen YI, Jenkins BG, Owen C, Livni E, et al. (2003) Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson’s disease model. NeuroImage 20:1064–1075
Otsuka M, Ichiya Y, Hosokawa S, Kuwabara Y, Tahara T, Fukumura T, et al. (1991) Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson’s disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry 54:898–904
Okada K, Suyama N, Oguro H, Yamaguchi S, Kobayashi S (1999) Medication-induced hallucination and cerebral blood flow in Parkinson’s disease. J Neurol 246:365–368
Emborg ME, Carbon M, Holden JE, During MJ, Ma Y, Tang C, et al. (2006) Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab (in press). DOI 10.1038/sj.jcbfm.9600364
Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, et al. (1996) Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson’s disease: a positron emission tomographic study. J Neurol Sci 144:77–83
Antonini A, Kazumata K, Feigin A, Mandel F, Dhawan V, Margouleff C, et al. (1998) Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov Disord 13:268–274
Klein RC, de Jong BM, de Vries JJ, Leenders KL (2005) Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson’s disease. Mov Disord 20:1021–1030
Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. (2005) FDG-PET in the differential diagnosis of parkinsonian disorders. NeuroImage 26:912–921
Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieres P, Antonini A, et al. (1999) Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 40:1264–1269
Trost M, Su PC, Barnes A, Su SL, Yen RF, Tseng HM, et al. (2003) Evolving metabolic changes during the first postoperative year after subthalamotomy. J Neurosurg 99:872–878
Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM (2004) Executive processes in Parkinson’s disease: FDG-PET and network analysis. Hum Brain Mapp 22:236–245
Kaasinen V, Maguire RP, Hundemer HP, Leenders KL (2006) Corticostriatal covariance patterns of 6-[18F]fluoro-l-dopa and [18F]fluorodeoxyglucose PET in Parkinson’s disease. J Neurol 253:340–348
Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, et al. (1995) Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. J Nucl Med 36:378–383
Eidelberg D, Moeller JR, Kazumata K, Antonini A, Sterio D, Dhawan V, et al. (1997) Metabolic correlates of pallidal neuronal activity in Parkinson’s disease. Brain 120:1315–1324
Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, et al. (2006) Network modulation in the treatment of Parkinson’s disease. Brain 129:2667–2678
Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D (2006) Metabolic brain networks associated with cognitive function in Parkinson’s disease. NeuroImage 34:714–723
Mentis MJ, McIntosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, et al. (2002) Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson’s disease. Am J Psychiatry 159:746–754
Spetsieris P, Ma Y, Dhawan V, Moeller JR, Eidelberg D. (2006) Highly automated computer-aided diagnosis of neurological disorders using functional brain imaging. Proc SPIE Int Soc Opt Eng-Medical Imaging 6144(5M):1–12
Feigin A, Antonini A, Fukuda M, De Notaris R, Benti R, Pezzoli G, et al. (2002) Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 17:1265–1270
Eckert T, Van Laere KV, Tang C, Lewis DE, Santens P, Eidelberg D (2006) Quantification of PD-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging (in press). DOI 10.1007/s00259-006-0261-9
Carroll TJ, Teneggi V, Jobin M, Squassante L, Treyer V, Hany TF, et al. (2002) Absolute quantification of cerebral blood flow with magnetic resonance, reproducibility of the method, and comparison with H2(15)O positron emission tomography. J Cereb Blood Flow Metab 22:1149–1156
Yen YF, Field AS, Martin EM, Ari N, Burdette JH, Moody DM, et al. (2002) Test–retest reproducibility of quantitative CBF measurements using FAIR perfusion MRI and acetazolamide challenge. Magn Reson Med 47:921–928
Spilt A, Box FM, van der Geest RJ, Reiber JH, Kunz P, Kamper AM, et al. (2002) Reproducibility of total cerebral blood flow measurements using phase contrast magnetic resonance imaging. J Magn Reson Imaging 16:1–5
Floyd TF, Ratcliffe SJ, Wang J, Resch B, Detre JA (2003) Precision of the CASL-perfusion MRI technique for the measurement of cerebral blood flow in whole brain and vascular territories. J Magn Reson Imaging 18:649–655
Huang C, Feigin A, Ma Y, Eidelberg D (2005) Imaging measures of longitudinal change in Parkinson’s disease. Neurology 64:A235
Sestini S, Scotto di Luzio A, Ammannati F, De Cristofaro MT, Passeri A, Martini S, et al. (2002) Changes in regional cerebral blood flow caused by deep-brain stimulation of the subthalamic nucleus in Parkinson’s disease. J Nucl Med 43:725–732
Ceballos-Baumann AO, Boecker H, Bartenstein P, von Falkenhayn I, Riescher H, Conrad B, et al. (1999) A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. Arch Neurol 56:997–1003
Schroeder U, Kuehler A, Lange KW, Haslinger B, Tronnier VM, Krause M, et al. (2003) Subthalamic nucleus stimulation affects a frontotemporal network: a PET study. Ann Neurol 54:445–450
Carbon M, Eidelberg D (2006) Functional imaging of sequence learning in Parkinson’s disease. J Neurol Sci 248:72–77
Su PC, Ma Y, Fukuda M, Mentis MJ, Tseng HM, Yen RF, et al. (2001) Metabolic changes following subthalamotomy for advanced Parkinson’s disease. Ann Neurol 50:514–520
Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, et al. (2001) Networks mediating the clinical effects of pallidal brain stimulation for Parkinson’s disease: a PET study of resting-state glucose metabolism. Brain 124:1601–1609
Trost M, Su S, Su P, Yen RF, Tseng HM, Barnes A, et al. (2006) Network modulation by the subthalamic nucleus in the treatment of Parkinson’s disease. NeuroImage 31:301–307
Hilker R, Voges J, Weisenbach S, Kalbe E, Burghaus L, Ghaemi M, et al. (2004) Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson’s disease. J Cereb Blood Flow Metab 24:7–16
Drucker-Colin R, Verdugo-Diaz L, Morgado-Valle C, Solis-Maldonado G, Ondarza R, Boll C, et al. (1999) Transplant of cultured neuron-like differentiated chromaffin cells in a Parkinson’s disease patient. A preliminary report. Arch Med Res 30:33–39
Feigin A, Tang C, Ma Y, Dhawan V, During MJ, Kaplitt MG, et al. (2006) Gene therapy for Parkinson’s disease with AAV-GAD: interim FDG-PET results. Neurology 66 (5, Suppl 2)
Aylward EH, Codori AM, Rosenblatt A, Sherr M, Brandt J, Stine OC, et al. (2000) Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease. Mov Disord 15:552–560
Rosas HD, Goodman J, Chen YI, Jenkins BG, Kennedy DN, Makris N, et al. (2001) Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 57:1025–1028
Thieben MJ, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F, et al. (2002) The distribution of structural neuropathology in pre-clinical Huntington’s disease. Brain 125:1815–1818
Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, et al. (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease. Brain 119:2085–2095
Weeks RA, Piccini P, Harding AE, Brooks DJ (1996) Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington’s disease. Ann Neurol 40:49–54
van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC, Veenma-van der Duin L, Pruim J, Roos RA, et al. (2005) Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 65:941–943
Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L (1997) Cognitive deficits in Huntington’s disease are predicted by dopaminergic PET markers and brain volumes. Brain 120:2207–2217
Antonini A, Leenders KL, Eidelberg D (1998) [11C]raclopride-PET studies of the Huntington’s disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 43:253–255
Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, et al. (1999) Huntington’s disease progression. PET and clinical observations. Brain 122:2353–2363
Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, et al. (2003) Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study. Brain 126:1127–1135
Araujo DM, Cherry SR, Tatsukawa KJ, Toyokuni T, Kornblum HI (2000) Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington’s disease. Exp Neurol 166:287–297
Kuwert T, Noth J, Scholz D, Schwarz M, Lange HW, Topper R, et al. (1993) Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of Huntington’s disease. Mov Disord 8:98–106
Hayden MR, Martin WR, Stoessl AJ, Clark C, Hollenberg S, Adam MJ, et al. (1986) Positron emission tomography in the early diagnosis of Huntington’s disease. Neurology 36:888–894
Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, et al. (1986) PET scan investigations of Huntington’s disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 20:296–303
Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, et al. (1988) Positron emission tomographic scan investigations of Huntington’s disease: cerebral metabolic correlates of cognitive function. Ann Neurol 23:541–546
Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE (1990) Cortical and subcortical glucose consumption measured by PET in patients with Huntington’s disease. Brain 113:1405–1423
Grafton ST, Mazziotta JC, Pahl JJ, St George-Hyslop P, Haines JL, Gusella J, et al. (1992) Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington’s disease. Arch Neurol 49:1161–1167
Martin WR, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR (1992) Cortical glucose metabolism in Huntington’s disease. Neurology 42:223–229
Sax DS, Powsner R, Kim A, Tilak S, Bhatia R, Cupples LA, et al. (1996) Evidence of cortical metabolic dysfunction in early Huntington’s disease by single-photon-emission computed tomography. Mov Disord 11:671–677
Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. (2006) Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med 47:215–222
Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR (2004) A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet 65:267–277
Ma Y, Feigin A, Rachakonda S, Dhawan V, Eidelberg D. (2006) Evolution of metabolic brain networks in presymptomatic Huntington’s disease: a longitudinal PET study. J Nucl Med 47:209p
Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P, et al. (2001) Metabolic network abnormalities in early Huntington’s disease: an [(18)F]FDG-PET study. J Nucl Med 42:1591–1595
Ma Y, Feigin A, Okulski J, Dhawan V, Chaly T, Eidelberg D (2003) Implementation of atrophy correction in metabolic mapping studies of presymptomatic Huntington’s disease. J Cereb Blood Flow Metab S629
Feigin A, Ghilardi MF, Huang C, Ma Y, Carbon M, Guttman M, et al. (2006) Preclinical Huntington’s disease: compensatory brain responses during learning. Ann Neurol 59:53–59
Hersch SM (2003) Huntington’s disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation. Curr Opin Neurol 16:501–506
Wang X, Sarkar A, Cicchetti F, Yu M, Zhu A, Jokivarsi K, et al. (2005) Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington’s disease. J Neurol Sci 231:57–66
Schumacher JM, Hantraye P, Brownell AL, Riche D, Madras BK, Davenport PD, et al. (1992) A primate model of Huntington’s disease: functional neural transplantation and CT-guided stereotactic procedures. Cell Transplant 1:313–322
Gaura V, Bachoud-Levi AC, Ribeiro MJ, Nguyen JP, Frouin V, Baudic S, et al. (2004) Striatal neural grafting improves cortical metabolism in Huntington’s disease patients. Brain 127:65–72
Furtado S, Sossi V, Hauser RA, Samii A, Schulzer M, Murphy CB, et al. (2005) Positron emission tomography after fetal transplantation in Huntington’s disease. Ann Neurol 58:331–337
Moro E, Lang AE, Strafella AP, Poon YY, Arango PM, Dagher A, et al. (2004) Bilateral globus pallidus stimulation for Huntington’s disease. Ann Neurol 56:290–294
Acknowledgement
This work was supported by NIH RO1 NS 35069 and 37564.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ma, Y., Eidelberg, D. Functional Imaging of Cerebral Blood Flow and Glucose Metabolism in Parkinson’s Disease and Huntington’s Disease. Mol Imaging Biol 9, 223–233 (2007). https://doi.org/10.1007/s11307-007-0085-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-007-0085-4